Skip to main content
. Author manuscript; available in PMC: 2015 Aug 15.
Published in final edited form as: Clin Cancer Res. 2014 Jun 9;20(16):4176–4185. doi: 10.1158/1078-0432.CCR-13-2024

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

A. Overall survival according to type of clinical trial (Phase II vs. Phase III). Cooperative group trials in advanced pancreatic cancer with regimens containing Gemcitabine. N=1,062. (N034A excluded.) B. Progression free survival according to type of clinical trial (Phase II vs. Phase III). Cooperative group trials in advanced pancreatic cancer with regimens containing Gemcitabine. N=1,062. (N034A excluded.) C. Overall survival according to time period of trial activation. Cooperative group trials in advanced pancreatic cancer with regimens containing Gemcitabine. N=1,062. (N034A excluded.) D. Progression free survival according to time period of trial activation. Cooperative group trials in advanced pancreatic cancer with regimens containing Gemcitabine. N=1,062. (N034A excluded.)